Cargando…

Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE

OBJECTIVE: Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Purmalek, Monica M, Carlucci, Philip M, Dey, Amit K, Sampson, Maureen, Temesgen-Oyelakin, Yenealem, Sakhardande, Simantini, Lerman, Joseph B, Fike, Alice, Davis, Michael, Chung, Jonathan H, Salahuddin, Taufiq, Manna, Zerai, Gupta, Sarthak, Chen, Marcus Y, Hasni, Sarfaraz, Mehta, Nehal N, Remaley, Alan, Kaplan, Mariana J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667837/
https://www.ncbi.nlm.nih.gov/pubmed/31413851
http://dx.doi.org/10.1136/lupus-2019-000332
_version_ 1783440107046436864
author Purmalek, Monica M
Carlucci, Philip M
Dey, Amit K
Sampson, Maureen
Temesgen-Oyelakin, Yenealem
Sakhardande, Simantini
Lerman, Joseph B
Fike, Alice
Davis, Michael
Chung, Jonathan H
Salahuddin, Taufiq
Manna, Zerai
Gupta, Sarthak
Chen, Marcus Y
Hasni, Sarfaraz
Mehta, Nehal N
Remaley, Alan
Kaplan, Mariana J
author_facet Purmalek, Monica M
Carlucci, Philip M
Dey, Amit K
Sampson, Maureen
Temesgen-Oyelakin, Yenealem
Sakhardande, Simantini
Lerman, Joseph B
Fike, Alice
Davis, Michael
Chung, Jonathan H
Salahuddin, Taufiq
Manna, Zerai
Gupta, Sarthak
Chen, Marcus Y
Hasni, Sarfaraz
Mehta, Nehal N
Remaley, Alan
Kaplan, Mariana J
author_sort Purmalek, Monica M
collection PubMed
description OBJECTIVE: Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) burden to predict coronary atherosclerosis in SLE. METHODS: Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy. RESULTS: SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low-density lipoprotein (VLDL) particle counts compared with controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared with controls. In contrast to high-sensitivity C reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance (IR), though the association with NCB was no longer significant after adjusting for prednisone use. CONCLUSIONS: Patients with SLE display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical labs, could be a useful tool in assessing CVD risk in patients with SLE.
format Online
Article
Text
id pubmed-6667837
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-66678372019-08-14 Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE Purmalek, Monica M Carlucci, Philip M Dey, Amit K Sampson, Maureen Temesgen-Oyelakin, Yenealem Sakhardande, Simantini Lerman, Joseph B Fike, Alice Davis, Michael Chung, Jonathan H Salahuddin, Taufiq Manna, Zerai Gupta, Sarthak Chen, Marcus Y Hasni, Sarfaraz Mehta, Nehal N Remaley, Alan Kaplan, Mariana J Lupus Sci Med Co-Morbidities OBJECTIVE: Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) burden to predict coronary atherosclerosis in SLE. METHODS: Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy. RESULTS: SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low-density lipoprotein (VLDL) particle counts compared with controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared with controls. In contrast to high-sensitivity C reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance (IR), though the association with NCB was no longer significant after adjusting for prednisone use. CONCLUSIONS: Patients with SLE display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical labs, could be a useful tool in assessing CVD risk in patients with SLE. BMJ Publishing Group 2019-07-12 /pmc/articles/PMC6667837/ /pubmed/31413851 http://dx.doi.org/10.1136/lupus-2019-000332 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Co-Morbidities
Purmalek, Monica M
Carlucci, Philip M
Dey, Amit K
Sampson, Maureen
Temesgen-Oyelakin, Yenealem
Sakhardande, Simantini
Lerman, Joseph B
Fike, Alice
Davis, Michael
Chung, Jonathan H
Salahuddin, Taufiq
Manna, Zerai
Gupta, Sarthak
Chen, Marcus Y
Hasni, Sarfaraz
Mehta, Nehal N
Remaley, Alan
Kaplan, Mariana J
Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title_full Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title_fullStr Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title_full_unstemmed Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title_short Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
title_sort association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in sle
topic Co-Morbidities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667837/
https://www.ncbi.nlm.nih.gov/pubmed/31413851
http://dx.doi.org/10.1136/lupus-2019-000332
work_keys_str_mv AT purmalekmonicam associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT carlucciphilipm associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT deyamitk associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT sampsonmaureen associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT temesgenoyelakinyenealem associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT sakhardandesimantini associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT lermanjosephb associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT fikealice associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT davismichael associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT chungjonathanh associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT salahuddintaufiq associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT mannazerai associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT guptasarthak associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT chenmarcusy associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT hasnisarfaraz associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT mehtanehaln associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT remaleyalan associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle
AT kaplanmarianaj associationoflipoproteinsubfractionsandglycoproteinacetylationwithcoronaryplaqueburdeninsle